Breaking News

Gilead to Acquire MYR GmbH for €1.15B

Gains Hepcludex, a first-in-class treatment for HDV; anticipates accelerated global launch as a result of the acquisition.

By: Contract Pharma

Contract Pharma Staff

Gilead Sciences, Inc. and MYR GmbH, a German biotechnology company focused on therapeutics for chronic hepatitis delta virus (HDV), have entered a definitive agreement under which Gilead will acquire MYR for approximately €1.15 billion in cash, plus a potential future milestone payment of up to €300 million. Gilead will gain Hepcludex (bulevirtide), which was conditionally approved by the European Medicines Agency (EMA) for the treatment of chronic HDV infection in adults with compensated li...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters